Download PDF
The Journal of Hip Surgery 2021; 05(01): 012-019
DOI: 10.1055/s-0041-1723758
Original Article

Aspirin Is Associated with Decreased Allogeneic Transfusions and Resource Utilization following Hip Fracture Care

Afshin A. Anoushiravani
1   Department of Surgery, Division of Orthopaedic Surgery, Albany Medical Center, Albany, New York
,
Zain Sayeed
2   Department of Orthopaedic Surgery and Sports Medicine, Detroit Medical Center, Detroit, Michigan
,
Benjamin V. Mori 
1   Department of Surgery, Division of Orthopaedic Surgery, Albany Medical Center, Albany, New York
,
Muhammad T. Padela
2   Department of Orthopaedic Surgery and Sports Medicine, Detroit Medical Center, Detroit, Michigan
3   Department of Orthopaedic Surgery, Rosalind Franklin University, Chicago Medical School, North Chicago, Illinois
,
Gonzalo Barinaga
4   Department of Surgery, Division of Orthopaedic Surgery, Southern Illinois School of Medicine, Springfield, Illinois
,
Paul J. Cagle
5   Department of Orthopaedic Surgery, Mount Sinai School of Medicine, New York, New York
,
Khaled J. Saleh
6   Michigan Musculoskeletal Institute, Madison Heights, Michigan
› Author Affiliations Funding The authors of this manuscript claim no source of external funding in the preparation of this work.
› Further Information
    Permissions and Reprints

Abstract

The purpose of our study is to assess the relationship and compare the impact of aspirin, enoxaparin, and warfarin use on postoperative anemia, allogenic transfusions, and resource utilization following hip fracture fixation. This is a retrospective study at a Level 1 trauma center with 450 geriatric hip fracture patients who underwent hip fracture surgery and chemoprophylaxis. Hip fracture patients were separated into three cohorts depending on the type of chemoprophylaxis administered aspirin, enoxaparin, or warfarin. Initially, all three cohorts were assessed for baseline characteristics, postoperative anemia, transfusion rates, and resource utilization. Next, aspirin and enoxaparin were comparatively evaluated for the same variables. Four hundred and fifty patients met inclusion criteria for the first portion of this study. No baseline variance was evident among the three cohorts except for body mass index (p = 0.007) and diagnosis of congestive heart failure (p = 0.001). Outcomes were insignificant for in-hospital mortality (p = 0.19), postoperative anemia (p = 0.43), hemoglobin levels (p = 0.91), and ∆hemoglobin (p = 0.99), length-of-stay (p = 0.12), disposition (p = 0.13), and 30-day readmission (p =0.09). The transfusion rate (p < 0.001) and hospital cost (p = 0.01) varied significantly among the prophylactic cohorts. Three hundred and eighty nine patients met inclusion criteria for the aspirin and enoxaparin comparison. Baseline characteristics between the cohorts only revealed a significant variance for age (p = 0.03). Outcomes did not vary significantly among aspirin and enoxaparin cohorts; however, hospital cost was 12.3% greater in patients receiving enoxaparin (p = 0.01). Our study compares administration of aspirin, warfarin, and enoxaparin as means of chemoprophylaxis following hip fracture repair. Analyses of outcomes demonstrated patients receiving warfarin were more likely to require transfusions. Additionally, when compared with aspirin, resource utilization was 16.9 and 12.3% greater with warfarin and enoxaparin, respectively. Thus, our study suggests that aspirin is a safe and cost-effective option for chemoprophylaxis following hip fracture fixation.

Keywords

hip fracture care - cost-effectiveness - VTE chemoprophylaxis - aspirin


Publication History

Received: 05 December 2020

Accepted: 10 November 2020

Article published online:
03 June 2021

© 2021. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Marks R, Allegrante JP, Ronald MacKenzie C, Lane JM. Hip fractures among the elderly: causes, consequences and control. Ageing Res Rev 2003; 2 (01) 57-93
    CrossrefPubMedGoogle Scholar
  • 2 Stevens JA, Rudd RA. The impact of decreasing U.S. hip fracture rates on future hip fracture estimates. Osteoporos Int 2013; 24 (10) 2725-2728
    CrossrefPubMedGoogle Scholar
  • 3 Hopkins RB, Pullenayegum E, Goeree R. et al. Estimation of the lifetime risk of hip fracture for women and men in Canada. Osteoporos Int 2012; 23 (03) 921-927
    CrossrefPubMedGoogle Scholar
  • 4 Nguyen ND, Ahlborg HG, Center JR, Eisman JA, Nguyen TV. Residual lifetime risk of fractures in women and men. J Bone Miner Res 2007; 22 (06) 781-788
    CrossrefPubMedGoogle Scholar
  • 5 Bateman L, Vuppala S, Porada P. et al. Medical management in the acute hip fracture patient: a comprehensive review for the internist. Ochsner J 2012; 12 (02) 101-110
    PubMedGoogle Scholar
  • 6 Powers PJ, Gent M, Jay RM. et al. A randomized trial of less intense postoperative warfarin or aspirin therapy in the prevention of venous thromboembolism after surgery for fractured hip. Arch Intern Med 1989; 149 (04) 771-774
    CrossrefPubMedGoogle Scholar
  • 7 Stewart DW, Freshour JE. Aspirin for the prophylaxis of venous thromboembolic events in orthopedic surgery patients: a comparison of the AAOS and ACCP guidelines with review of the evidence. Ann Pharmacother 2013; 47 (01) 63-74
    CrossrefPubMedGoogle Scholar
  • 8 Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet 2000; 355 (9212): 1295-1302
    CrossrefPubMedGoogle Scholar
  • 9 Duerschmied D, Nitschmann S, Bode C. [Prevention of recurrent thromboembolisms: WARFASA (aspirin for the prevention of recurrent venous thromboembolism - the Warfarin and Aspirin Study)]. Internist (Berl) 2013; 54 (11) 1393-1396
    CrossrefPubMedGoogle Scholar
  • 10 Birocchi S, Scannella E, Ferrari L, Podda GM. Gruppo di Autoformazione Metodologica (GrAM). Aspirin in the secondary prevention of unprovoked thromboembolism: the WARFASA and ASPIRE studies. Intern Emerg Med 2013; 8 (08) 757-760
    CrossrefPubMedGoogle Scholar
  • 11 Anderson DR, Dunbar MJ, Bohm ER. et al. Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial. Ann Intern Med 2013; 158 (11) 800-806
    CrossrefPubMedGoogle Scholar
  • 12 Davenport DL, Bowe EA, Henderson WG, Khuri SF, Mentzer Jr RM. National Surgical Quality Improvement Program (NSQIP) risk factors can be used to validate American Society of Anesthesiologists Physical Status Classification (ASA PS) levels. Ann Surg 2006; 243 (05) 636-641 , discussion 641–644
    CrossrefPubMedGoogle Scholar
  • 13 Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40 (05) 373-383
    CrossrefPubMedGoogle Scholar
  • 14 Radovanovic D, Seifert B, Urban P. et al; AMIS Plus Investigators. Validity of Charlson Comorbidity Index in patients hospitalised with acute coronary syndrome. Insights from the nationwide AMIS Plus registry 2002-2012. Heart 2014; 100 (04) 288-294
    CrossrefPubMedGoogle Scholar
  • 15 Falck-Ytter Y, Francis CW, Johanson NA. et al. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2, Suppl): e278S-e325S
    CrossrefPubMedGoogle Scholar
  • 16 Patel VP, Walsh M, Sehgal B, Preston C, DeWal H, Di Cesare PE. Factors associated with prolonged wound drainage after primary total hip and knee arthroplasty. J Bone Joint Surg Am 2007; 89 (01) 33-38
    CrossrefPubMedGoogle Scholar
  • 17 Saleh K, Olson M, Resig S. et al. Predictors of wound infection in hip and knee joint replacement: results from a 20 year surveillance program. J Orthop Res 2002; 20 (03) 506-515
    CrossrefPubMedGoogle Scholar
  • 18 Foss NB, Kehlet H. Hidden blood loss after surgery for hip fracture. J Bone Joint Surg Br 2006; 88 (08) 1053-1059
    CrossrefPubMedGoogle Scholar
  • 19 Blumberg N, Kirkley SA, Heal JM. A cost analysis of autologous and allogeneic transfusions in hip-replacement surgery. Am J Surg 1996; 171 (03) 324-330
    CrossrefPubMedGoogle Scholar
  • 20 Fisher WD, Agnelli G, George DJ. et al. Extended venous thromboembolism prophylaxis in patients undergoing hip fracture surgery - the SAVE-HIP3 study. Bone Joint J 2013; 95-B (04) 459-466
    CrossrefPubMedGoogle Scholar
  • 21 Lip GY, Gibbs CR. Does heart failure confer a hypercoagulable state? Virchow's triad revisited. J Am Coll Cardiol 1999; 33 (05) 1424-1426
    CrossrefPubMedGoogle Scholar
  • 22 Shantsila E, Lip GY. Antiplatelet versus anticoagulation treatment for patients with heart failure in sinus rhythm. Cochrane Database Syst Rev 2016; 9: CD003333
    PubMedGoogle Scholar
  • 23 Hopper I, Skiba M, Krum H. Updated meta-analysis on antithrombotic therapy in patients with heart failure and sinus rhythm. Eur J Heart Fail 2013; 15 (01) 69-78
    CrossrefPubMedGoogle Scholar
  • 24 Homma S, Thompson JL, Pullicino PM. et al; WARCEF Investigators. Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med 2012; 366 (20) 1859-1869
    CrossrefPubMedGoogle Scholar
  • 25 Bell JJ, Bauer JD, Capra S, Pulle RC. Quick and easy is not without cost: implications of poorly performing nutrition screening tools in hip fracture. J Am Geriatr Soc 2014; 62 (02) 237-243
    CrossrefPubMedGoogle Scholar
  • 26 White PJ. Patient factors that influence warfarin dose response. J Pharm Pract 2010; 23 (03) 194-204
    CrossrefPubMedGoogle Scholar
  • 27 Berg TM, O'Meara JG, Ou NN. et al. Risk factors for excessive anticoagulation among hospitalized adults receiving warfarin therapy using a pharmacist-managed dosing protocol. Pharmacotherapy 2013; 33 (11) 1165-1174
    CrossrefPubMedGoogle Scholar
  • 28 Alonso-Coello P, Bellmunt S, McGorrian C. et al. Antithrombotic therapy in peripheral artery disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2, Suppl): e669S-e690S
    CrossrefPubMedGoogle Scholar
  • 29 Jameson SS, Charman SC, Gregg PJ, Reed MR, van der Meulen JH. The effect of aspirin and low-molecular-weight heparin on venous thromboembolism after hip replacement: a non-randomised comparison from information in the National Joint Registry. J Bone Joint Surg Br 2011; 93 (11) 1465-1470
    CrossrefPubMedGoogle Scholar
  • 30 Hamilton SC, Whang WW, Anderson BJ, Bradbury TL, Erens GA, Roberson JR. Inpatient enoxaparin and outpatient aspirin chemoprophylaxis regimen after primary hip and knee arthroplasty: a preliminary study. J Arthroplasty 2012; 27 (09) 1594-1598
    CrossrefPubMedGoogle Scholar
  • 31 Dorr LD, Gendelman V, Maheshwari AV, Boutary M, Wan Z, Long WT. Multimodal thromboprophylaxis for total hip and knee arthroplasty based on risk assessment. J Bone Joint Surg Am 2007; 89 (12) 2648-2657
    CrossrefPubMedGoogle Scholar